Clinical Trial Update: Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating trastuzumab plus a taxane as neoadjuvant therapy for HER2-positive ductal carcinoma in situ of the breast, with enrollme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Drugs mentioned

• Taxane (paclitaxel or docetaxel)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Carcinoma in Situ | Phase 2 | Status: ENROLLING_BY_INVITATION